不眠症治療の世界市場-2023年～2030年

概要

世界の不眠症治療市場は、2022年に37億米ドルに達し、2023～2030年の予測期間中にCAGR 4.3％で成長し、2030年には51億米ドルに達すると予測されています。

不眠症は、入眠、睡眠維持、質の良い睡眠を得ることが困難な睡眠障害です。短期不眠症は、ストレスやスケジュールや環境の変化によって引き起こされ、数日から数週間続くことがあります。慢性不眠症または長期不眠症は、週に3日以上、または3ヵ月以上続きます。

世界の不眠症治療市場は、エスタゾラム、テマゼパム、クアゼパムなどのベンゾジアゼピン系薬剤の摂取により、近年著しい成長を遂げています。テマゼパムは、不眠症に最もよく処方されるベンゾジアゼピン系薬剤です。不眠症治療薬の選択は、希望する作用の発現と持続時間に基づいています。

さらに、ストレスレベルの増加、製品の発売、研究開発の活発化などの重要な成長要因が、将来の市場成長をもたらします。Merck &Co.、Pfizer Inc.、Abbott、Eisai Ltd.、Idorsia Pharmaceuticals、その他の主要企業が市場で活発に活動しています。

ダイナミクス

人々のストレスレベルの上昇が市場成長を促進する見込み

世界中で人々のストレスレベルが上昇していることが、主な促進要因となっています。ストレスや不安はしばしば不眠症につながり、ストレスの多いライフイベントやトラウマは睡眠障害の主な原因です。いくつかの心理的・生理的要因が、不安・反省的な性格特性やストレスの多い出来事など、不眠症の発症や持続に寄与しています。

例えば、2021年12月に発表されたHealth and Safety Executiveの報告によると、2020-2021年には822,000人以上の労働者が仕事に関連したストレス、うつ病、不安に苦しんでいます。従業員から報告された過度の職業性ストレスは32.8％となっています。回答者の半数以上（51％）が抑うつ症状を報告し、約11％が不眠症と診断されたと報告しました。

不眠症治療に対するFDA承認の増加が市場成長を促進すると予想される

規制当局による治療認可の増加は、市場の成長を後押しします。FDAから承認を得る過程では、一般的に疾患の動物モデルを用いた前臨床実験が行われます。動物モデル実験の結果が良好であれば、FDAは介入研究の構成案を承認することができます。

例えば、2022年12月、ザイダス・ライフサイエンシズ・リミテッドは、不眠症の治療に短期間使用されるトリアゾラム錠剤のジェネリック医薬品の販売について、米国FDAから最終承認を取得しました。この薬は、不眠症や入眠障害、睡眠維持障害の治療に短期間使用されます。睡眠を可能にするために脳の活動を鈍らせることによって作用します。

不眠症治療薬に伴う副作用

市販の処方睡眠薬は、便秘、口渇、頭痛、消化器系の問題を引き起こす可能性があります。クリーブランド・クリニックによると、睡眠薬を服用した翌日、10人中約8人が二日酔い効果を経験します。二日酔いは、眠気、思考の混乱、めまいや平衡感覚の問題を引き起こします。

こうした日中の影響は、車の運転や仕事、日常業務をこなす能力に悪影響を及ぼしかねません。処方された睡眠薬の中には、パラソムニア（睡眠時随伴症）を引き起こすものがほとんどなく、この睡眠障害は、本人がまだほとんど眠っている間に危険な行動を引き起こす可能性があります。したがって、上記の要因のために、市場は予測期間中に低迷すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 人々のストレスレベルの上昇
    • 不眠症治療に対するFDA承認の増加
  • 抑制要因
    • 不眠症治療薬に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• DMIの見解

第6章 COVID-19分析

第7章 タイプ別

• 急性不眠症
• 慢性不眠症
• 入眠障害
• 持続性不眠症
• 小児行動性不眠症

第8章 薬剤別

• エスゾピクロン
• ラメルテオン
• ザレプロン
• ゾルピデム
• エスタゾラム
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な動向と戦略

第12章 企業プロファイル

• Merck & Co.
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Pfizer Inc.
• Abbott
• Genentech
• LGM Pharma
• Sigma Aldrich
• Sanofi S.A
• Takeda Pharmaceuticals
• Eisai Ltd.
• Idorsia Pharmaceuticals

第13章 付録

Overview

Global Insomnia Treatment Market reached US$ 3.7 billion in 2022 and is expected to reach US$ 5.1 billion by 2030 growing with a CAGR of 4.3% during the forecast period 2023-2030.

Insomnia is a sleep disorder that trouble falling asleep, staying asleep, and getting good quality sleep. Short-term insomnia is caused by stress or changes in the schedule or environment and this can last for a few days or weeks. Chronic or long-term insomnia occurs 3 or more nights a week or lasts more than 3 months.

The global insomnia treatment market has witnessed significant growth in recent years due to the intake of benzodiazepine drugs such as estazolam, temazepam, and quazepam. Temazepam is the most commonly prescribed benzodiazepine drug for insomnia. The choice of insomnia drug is based on the desired onset and duration of action.

Furthermore, significant growth drivers such as increasing stress levels, product launches, and rising research and developments give rise to future market growth. Significant key players like Merck & Co., Pfizer Inc., Abbott, Eisai Ltd., Idorsia Pharmaceuticals, and others are actively operating in the market.

Dynamics

Rising Stress Levels Among People is Expected to Boost the Market Growth

The rising stress levels among people across the globe act as a primary driver. Stress and anxiety often lead to insomnia and stressful life events or trauma are the main causes of sleeping disorders. Several psychological and physiological factors contribute to the onset and perpetuation of insomnia, such as anxious-ruminative personality traits, and stressful events.

For instance, According to the Health and Safety Executive report published in December 2021, over 822,000 workers suffered from work-related stress, depression, or anxiety in 2020-2021. Excessive occupational stress reported by the employees was 32.8%. More than half of respondents (51%) reported depressive symptoms and around 11% reported being diagnosed with insomnia.

Rising FDA Approvals for Insomnia Treatment is Expected to Boost the Market Growth

The increase in treatment approvals by regulatory bodies helps to drive market growth. The process of getting approval from the FDA generally involves preclinical experiments in an animal model of the disease. If the results of the animal model experiments are favorable then the FDA can approve the proposed structure of an interventional study.

For instance, in December 2022, Zydus Lifesciences Ltd received final approval from the US FDA to market its generic version of Triazolam tablets used on a short-term basis to treat insomnia. The medicine is used on a short-term basis to treat insomnia and difficulty falling asleep or staying asleep. It works by slowing activity in the brain to allow sleep.

Side Effects Associated with Insomnia Drugs

Over-the-counter prescription sleeping pills can cause constipation, dry mouth, headaches, and digestive problems. According to Cleveland Clinic, approximately 8 out of 10 people experience a hangover effect the day after taking sleep medicine. It leads to drowsiness, muddled thinking, and experience dizziness or balance problems.

These daytime effects can negatively impact the ability to drive, work, and complete daily tasks. Few prescription sleep medicines can bring on parasomnia and this disruptive sleep disorder can cause dangerous behaviors while the person is still mostly asleep. Hence, owing to the above factors, the market is expected to hamper over the forecast period.

For more details on this report - Request for Sample

Segment Analysis

The global insomnia treatment market is segmented based on type, treatment, distribution channel and region.

Chronic Insomnia from the Type Segment Accounted for Approximately 47.3% of the Global Insomnia Treatment Market Share

The rising treatment drug approvals globally have contributed to the growing demand for the insomnia treatment market. For instance, in June 2023, Idorsia Ltd launched QUVIVIQ (daridorexant) in Switzerland which is a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning. QUVIVIQ is the first dual orexin receptor antagonist (DORA) available in Switzerland for the treatment of chronic insomnia disorder.

Additionally, in February 2021, Eisai Co., Ltd., its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with chronic insomnia which is characterized by difficulties with sleep onset or sleep maintenance.

Geographical Penetration

North America Accounted for Approximately 38.4% of the Market Share in 2022

North America has maintained a significant proportion of the insomnia treatment market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence of sleep disorders, organizations specific to insomnia, and research and developments in insomnia treatment.

For instance, according to the Sleep Foundation data published in 2023, it estimates around 50 million to 70 million people in the U.S. have ongoing sleep disorders. Approximately, 9% to 15% of U.S. adults have insomnia that affects their daytime activities. Among them, 40% of women are more likely to have insomnia than men.

Competitive Landscape

The major global players in the market include: Merck & Co., Pfizer Inc., Abbott, Genentech, LGM Pharma, Sigma Aldrich Sanofi S.A, Takeda Pharmaceuticals, Eisai Ltd., Idorsia Pharmaceuticals. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the insomnia treatment market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in insomnia treatment research and product launches. Clinical trials are vital for developing new treatments and improving outcomes in the insomnia treatment market.

However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the insomnia treatment market is expected to be moderately affected over the forecast period.

By Type

• Acute Insomnia
• Chronic Insomnia.
• Onset Insomnia.
• Maintenance Insomnia.
• Behavioral Insomnia of Childhood

By Drugs

• Eszopiclone
• Ramelteon
• Zaleplon
• Zolpidem
• Estazolam
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In June 2022, Pear Therapeutics received marketing authorization from the FDA for Somryst, its prescription digital therapeutic for adults with chronic insomnia. The treatment provides cognitive behavioral therapy for insomnia (CBTi) alongside personalized, algorithm-generated sleep restriction recommendations.
• In April 2022, Bukwang Pharmaceutical launched the Zaledeep Cap for the treatment of insomnia patients which is the first treatment in Korea that uses zaleplon as a main ingredient.

Why Purchase the Report?

• To visualize the global insomnia treatment market segmentation based on type, drugs, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global insomnia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global insomnia treatment market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drugs
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising stress levels among people
    • 4.1.1.2. Increasing FDA approvals for insomnia treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with insomnia drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Acute Insomnia
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Chronic Insomnia
• 7.4. Onset Insomnia
• 7.5. Maintenance Insomnia
• 7.6. Behavioral Insomnia of Childhood

8. By Drugs

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 8.1.2. Market Attractiveness Index, By Drugs
• 8.2. Eszopiclone
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Ramelteon
• 8.4. Zaleplon
• 8.5. Zolpidem
• 8.6. Estazolam
• 8.7. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacy
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacy
• 9.4. Online Pharmacy
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Product Benchmarking
• 11.3. Company Share Analysis
• 11.4. Key Developments and Strategies

12. Company Profiles

• 12.1. Merck & Co.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Pfizer Inc.
• 12.3. Abbott
• 12.4. Genentech
• 12.5. LGM Pharma
• 12.6. Sigma Aldrich
• 12.7. Sanofi S.A
• 12.8. Takeda Pharmaceuticals
• 12.9. Eisai Ltd.
• 12.10. Idorsia Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us